Report cover image

Uterine Cancer Therapeutics & Diagnostics Market by Cancer Type (Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma), Product (Diagnostics, Therapeutics) - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 184 Pages
SKU # IRE18451364

Description

Uterine Cancer Therapeutics & Diagnostics Market by Cancer Type (Adenosquamous Carcinoma, Endometrial Adenocarcinoma, Papillary Serous Carcinoma), Product (Diagnostics, Therapeutics) - Global Forecast 2024-2030


The Uterine Cancer Therapeutics & Diagnostics Market size was estimated at USD 22.55 billion in 2023 and expected to reach USD 23.95 billion in 2024, at a CAGR 6.29% to reach USD 34.59 billion by 2030.

Global Uterine Cancer Therapeutics & Diagnostics Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Uterine Cancer Therapeutics & Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Uterine Cancer Therapeutics & Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Uterine Cancer Therapeutics & Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Ability Pharma, AstraZeneca PLC, BioMerieux S.A., Danaher Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Uterine Cancer Therapeutics & Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Cancer Type
Adenosquamous Carcinoma
Endometrial Adenocarcinoma
Papillary Serous Carcinoma
Uterine Sarcoma
Product
Diagnostics
Biopsy

CT Scan

Dilation & Curettage

Hysteroscopy

Pelvic Ultrasound
Therapeutics
Chemotherapy

Immunotherapy

Radiation Therapy

Surgery
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Uterine Cancer Therapeutics & Diagnostics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Uterine Cancer Therapeutics & Diagnostics Market?
3. What are the technology trends and regulatory frameworks in the Uterine Cancer Therapeutics & Diagnostics Market?
4. What is the market share of the leading vendors in the Uterine Cancer Therapeutics & Diagnostics Market?
5. Which modes and strategic moves are suitable for entering the Uterine Cancer Therapeutics & Diagnostics Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

184 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Uterine Cancer Therapeutics & Diagnostics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness of uterine cancer in physicians and healthcare providers
5.1.1.2. Rising in importance of the women health
5.1.1.3. Increasing healthcare expenditure and rising focus of government on providing adequate healthcare solutions
5.1.2. Restraints
5.1.2.1. Expensive treatment methods along with adverse side effects and severe toxicity of the medications
5.1.3. Opportunities
5.1.3.1. Increasing advancements in the cancer screening and treatment methods
5.1.3.2. Developing countries organising various programmes about uterine cancer severity and importance
5.1.4. Challenges
5.1.4.1. Low success rate of cancer drug clinical trials
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Uterine Cancer Therapeutics & Diagnostics Market, by Cancer Type
6.1. Introduction
6.2. Adenosquamous Carcinoma
6.3. Endometrial Adenocarcinoma
6.4. Papillary Serous Carcinoma
6.5. Uterine Sarcoma
7. Uterine Cancer Therapeutics & Diagnostics Market, by Product
7.1. Introduction
7.2. Diagnostics
7.3.1. Biopsy
7.3.2. CT Scan
7.3.3. Dilation & Curettage
7.3.4. Hysteroscopy
7.3.5. Pelvic Ultrasound
7.3. Therapeutics
7.4.1. Chemotherapy
7.4.2. Immunotherapy
7.4.3. Radiation Therapy
7.4.4. Surgery
8. Americas Uterine Cancer Therapeutics & Diagnostics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Abbott Laboratories
12.1.2. AbbVie Inc.
12.1.3. Ability Pharma
12.1.4. AstraZeneca PLC
12.1.5. BioMerieux S.A.
12.1.6. Danaher Corporation
12.1.7. Eli Lilly and Company
12.1.8. F. Hoffmann-La Roche AG
12.1.9. GlaxoSmithKline PLC
12.1.10. Johnson & Johnson Services, Inc.
12.1.11. Merck & Co., Inc.
12.1.12. Pfizer Inc.
12.1.13. Sanofi S.A.
12.1.14. Siemens Healthineers AG
12.1.15. Takeda Pharmaceutical Co. Ltd.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
FIGURE 8. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 10. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. UTERINE CANCER THERAPEUTICS & DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us